All In Biotech

Drug Trial Radar · NCT06826313

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 19, 2025

Primary completion

Dec 30, 2028

Study completion Mar 1, 2029

Sponsor

Sponsor type
Industry
Collaborators
Third Affiliated Hospital, Sun Yat-Sen University
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors

Conditions

  • Solid Tumors

Interventions

  • VRT106Biological

    Intravenous drip administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with advanced malignanttumorsTime frame: About 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.